Therapeutic hypothermia is currently the only clinically approved therapy to treat neurological injury across the central nervous system in the setting of cardiac arrest and other similar conditions, but it comes with a risk of adverse side effects. New therapies are desperately needed to restore normal brain function; however, compounds that inhibit activity of Pleckstrin homology domain leucine-rich repeat protein phosphatases (PHLPP) and promote AKT activity—the standard for neuroprotection in prior art—typically have limited ability to cross the blood brain barrier (BBB), a critical component for effectiveness, due to their chemical-structural property and high albumin binding. The BBB is a major obstacle in developing novel CNS-active small-molecule drugs, and thus, compounds that are expected to have neuroprotective abilities are unable to reach the locations where they are most needed.